Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.
Saved in:
| Title: | Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. |
|---|---|
| Authors: | Kos Z; Department of Pathology, BC Cancer - Vancouver, Vancouver, BC Canada., Roblin E; 2Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.; 3Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France., Kim RS; 4National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology, Pittsburgh, PA USA., Michiels S; 2Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.; 3Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France., Gallas BD; 5Division of Imaging, Diagnostics, and Software Reliability (DIDSR); Office of Science and Engineering Laboratories (OSEL); Center for Devices and Radiological Health (CDRH), US Food and Drug Administration (US FDA), Silver Spring, MD USA., Chen W; 5Division of Imaging, Diagnostics, and Software Reliability (DIDSR); Office of Science and Engineering Laboratories (OSEL); Center for Devices and Radiological Health (CDRH), US Food and Drug Administration (US FDA), Silver Spring, MD USA., van de Vijver KK; 6Department of Pathology, University Hospital Antwerp, Antwerp, Belgium.; 7Department of Pathology, Ghent University Hospital, Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Goel S; 8The Sir Peter MacCallum Cancer Centre, Melbourne, VIC Australia.; 9Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria Australia., Adams S; 10Perlmutter Cancer Center, New York University Medical School, New York, NY USA., Demaria S; 11Departments of Radiation Oncology and Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY USA., Viale G; 12Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy., Nielsen TO; 13Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada., Badve SS; 14Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA., Symmans WF; 15Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX USA., Sotiriou C; 16Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Rimm DL; 17Department of Pathology, Yale School of Medicine, New Haven, CT USA., Hewitt S; 18Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD USA., Denkert C; 19Institute of Pathology, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg and Philipps-Universität Marburg, Marburg, Germany., Loibl S; 20German Breast Group, Neu-Isenburg, Germany., Luen SJ; 9Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria Australia.; 21Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia., Bartlett JMS; 22Ontario Institute for Cancer Research, Toronto, ON Canada.; 23University of Edinburgh Cancer Research Centre, Edinburgh, UK., Savas P; 9Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria Australia.; 21Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia., Pruneri G; 24Department of Pathology, IRCCS Fondazione Instituto Nazionale Tumori and University of Milan, School of Medicine, Milan, Italy., Dillon DA; 25Department of Pathology, Brigham and Women's Hospital, Boston, MA USA.; 26Department of Pathology, Dana Farber Cancer Institute, Boston, MA USA., Cheang MCU; 27Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research, Surrey, UK., Tutt A; 28Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Hall JA; Vivactiv Ltd, Bellingdon, Bucks, UK., Kok M; 30Department of Medical Oncology and Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Horlings HM; 6Department of Pathology, University Hospital Antwerp, Antwerp, Belgium.; 31Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Madabhushi A; 32Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH USA.; 33Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH USA., van der Laak J; 34Computational Pathology Group, Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands., Ciompi F; 34Computational Pathology Group, Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands., Laenkholm AV; 35Department of Surgical Pathology Zealand University Hospital, Køge, Denmark., Bellolio E; 36Departamento de Anatomía Patológica, Universidad de La Frontera, Temuco, Chile., Gruosso T; Forbius, Montreal, QC Canada., Fox SB; 8The Sir Peter MacCallum Cancer Centre, Melbourne, VIC Australia.; 38Department of Pathology, Peter MacCallum Cancer Centre Department of Pathology, Melbourne, VIC Australia., Araya JC; 39Department of Pathology, Universidad de la Frontera, Temuco, Chile., Floris G; 40KU Leuven- Univerisity of Leuven, Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research and KU Leuven- University Hospitals Leuven, Department of Pathology, Leuven, Belgium., Hudeček J; 41Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Voorwerk L; 42Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Beck AH; 43PathAI, Inc, Boston, MA USA., Kerner J; 43PathAI, Inc, Boston, MA USA., Larsimont D; 44Department of Pathology, Jules Bordet Institute, Brussels, Belgium., Declercq S; Department of Pathology, GZA-ZNA, Antwerp, Belgium., Van den Eynden G; Department of Pathology, GZA-ZNA, Antwerp, Belgium., Pusztai L; 46Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT USA., Ehinger A; 47Department of Clinical Genetics and Pathology, Skåne University Hospital, Lund University, Lund, Sweden., Yang W; 48Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China., AbdulJabbar K; 49Centre for Evolution and Cancer; Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Yuan Y; 49Centre for Evolution and Cancer; Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Singh R; 50Icahn School of Medicine at Mt. Sinai, New York, NY 10029 USA., Hiley C; 51Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK., Bakir MA; 51Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK., Lazar AJ; 52Departments of Pathology, Genomic Medicine, Dermatology, and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA., Naber S; 53Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, USA., Wienert S; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany., Castillo M; 55Department of Medical Oncology and Research, Instituto Nacional de Enfermedades Neoplasicas, Lima, 15038 Peru., Curigliano G; 56University of Milan, Istituto Europeo di Oncologia, IRCCS, Milan, Italy., Dieci MV; 57Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.; 58Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy., André F; 59Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France., Swanton C; 51Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; 60Francis Crick Institute, Midland Road, London, UK., Reis-Filho J; 61Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA.; 62Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY USA., Sparano J; 63Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY USA., Balslev E; 64Department of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark., Chen IC; 65Department of Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.; 66Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; 67Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan., Stovgaard EIS; 64Department of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark., Pogue-Geile K; 4National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology, Pittsburgh, PA USA., Blenman KRM; 46Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT USA., Penault-Llorca F; 68Centre de Lutte contre le cancer - Centre Jean Perrin, Clermont-Ferrand, France., Schnitt S; 25Department of Pathology, Brigham and Women's Hospital, Boston, MA USA., Lakhani SR; 69The University of Queensland Centre for Clinical Research and Pathology Queensland, Brisbane, QLD Australia., Vincent-Salomon A; Institut Curie, Paris Sciences Lettres Université, Inserm U934, Department of Pathology, Paris, France., Rojo F; 71Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD) - CIBERONC, Madrid, Spain.; 72GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain., Braybrooke JP; 73Nuffield Department of Population Health, University of Oxford, Oxford and Department of Medical Oncology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK., Hanna MG; 61Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA., Soler-Monsó MT; 74Department of Pathology, Bellvitge University Hospital, IDIBELL. Breast Unit. Catalan Institut of Oncology. L 'Hospitalet del Llobregat', Barcelona, 08908 Catalonia Spain., Bethmann D; 75University Hospital Halle (Saale), Institute of Pathology, Halle (Saale), Germany., Castaneda CA; 55Department of Medical Oncology and Research, Instituto Nacional de Enfermedades Neoplasicas, Lima, 15038 Peru., Willard-Gallo K; 76Molecular Immunology Unit, Institut Jules Bordet, Universitè Libre de Bruxelles, Brussels, Belgium., Sharma A; 77Department of Biomedical Informatics, Emory University, Atlanta, GA USA., Lien HC; 78Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan., Fineberg S; 79Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY USA., Thagaard J; 80DTU Compute, Department of Applied Mathematics, Technical University of Denmark; Visiopharm A/S, Hørsholm, Denmark., Comerma L; 72GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain.; 81Pathology Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain., Gonzalez-Ericsson P; 82Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN USA., Brogi E; 61Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA., Loi S; 9Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria Australia.; 21Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia., Saltz J; 83Biomedical Informatics Department, Stony Brook University, Stony Brook, NY USA., Klaushen F; 84Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany., Cooper L; 85Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL USA., Amgad M; 86Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA USA., Moore DA; 87Department of Pathology, UCL Cancer Institute, UCL, London, UK.; 88University College Hospitals NHS Trust, London, UK., Salgado R; 21Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia.; Department of Pathology, GZA-ZNA, Antwerp, Belgium. |
| Corporate Authors: | International Immuno-Oncology Biomarker Working Group |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2020 May 12; Vol. 6, pp. 17. Date of Electronic Publication: 2020 May 12 (Print Publication: 2020). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: eCollection Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2374-4677 |
|---|---|
| DOI: | 10.1038/s41523-020-0156-0 |
